Lobbying Documents/Talking Points/Additional Resources

• PCMA “Delinking” Fact Sheet
• PCMA “Delinking” Myth vs. Fact
• PCMA Pharma “Delinking” One Pager
• Senate Messaging Points: Includes “delinking” and spread-specific points
• The DRUG Act Would Not Lower Drug Prices But Would Increase Costs for Taxpayers, Employers and Patients 
• “Delinking” Means Drug Companies Win, While Taxpayers and Patients Lose
• Misunderstanding Means Misalignment 
• The Economic Impact of “Delinking” 
• The Truth About Rebates
• What Would “Delinking” Do to Employers?
• Infographic: Rebates Unrelated to Drug Costs
• Infographic: Share of Drug Dollar by Drug Supply Chain Participants
• PBM Legislative Landscape Chart
• Senate Finance Committee November Markup Summary and Talking Points
• PCMA Statement on Finance Committee Vote  
• PCMA Blog: National Bureau of Economic Research Working Paper: “Delinking” Proposals that Restrict PBM Incentives to Secure Rx Savings Will Increase Drug Prices and Provide $10B Giveaway for Big Pharma
• Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
• Federal Coalition Letter
• CCAGW Urges Senate Finance Committee to Oppose Draft PBM Legislation
• PCMA Statement: Big Pharma Backed “Delinking” Legislation Threatens to Significantly Increase Prescription Drug Costs in Commercial Market
• Stop the Billion Dollar Big Pharma Bailout
• High drug costs start and end with big drug companies
• A World Without Pharmacy Benefit Companies…
• “Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
• Big Pharma Backed “Delinking” Legislation Threatens to Significantly Increase Prescription Drug Costs in Commercial Market
• Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
• Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
• New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma

Supportive Research

• Casey Mulligan/NBER: Ending Pay for PBM Performance – Consequences for Prescription Drug Prices, Utilization, and Government Spending 
• Alex Brill/Matrix Global Advisors: The Economics of “Delinking” PBM Compensation
• Infographic: New Research by Lawton Burns Investigates the Role of PBMs in the Healthcare Value Chain 
• Joel Zinberg/Competitive Enterprise Institute: A Free Market Solution for Drug Distribution
• Coalition for Affordable Prescription Drugs: Anti-PBM Legislation Eliminates Services And Choices That Employers Overwhelmingly Value
• Brookings Institute: A brief look at current debates about pharmacy benefit managers

Published Op-Eds

• Joel Zinberg: Restricting Pharmacy Benefit Managers Could Decrease Competition and Increase Drug Costs
• Pat Toomey: Before Targeting PBMs, Republicans Should Consider the Unintended Consequences
• Joe Grogan: Congress Wants a Better Value. So Why Are They Eliminating Performance Based Payment?
• Ike Brannon: The Problem with Delinking in Drug Price Negotiations
• Daniel Tecler, a health care sales representative, in Florida Politics.